pp 1–10 | Cite as

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis

  • Ana Luisa Perdigoto
  • Paula Preston-Hurlburt
  • Pamela Clark
  • S. Alice Long
  • Peter S. Linsley
  • Kristina M. Harris
  • Steven E. Gitelman
  • Carla J. Greenbaum
  • Peter A. Gottlieb
  • William Hagopian
  • Alyssa Woodwyk
  • James Dziura
  • Kevan C. Herold
  • the Immune Tolerance Network



The long-term effects of successful immune therapies for treatment of type 1 diabetes have not been well studied. The Autoimmunity-Blocking Antibody for Tolerance (AbATE) trial evaluated teplizumab, an Fc receptor non-binding humanised anti-CD3 monoclonal antibody in individuals with new-onset type 1 diabetes, and ended in 2011. Clinical drug-treated responders showed an increased frequency of ‘partially exhausted’ CD8+ T cells. We studied the clinical, immunological and metabolic status of participants after an average follow-up of 7 years.


Participants with detectable C-peptide at year 2 of AbATE returned for follow-up. C-peptide responses were assessed by 4 h mixed-meal tolerance test. Autoantibodies and HbA1c levels were measured and average daily insulin use was obtained from patient logs. Peripheral blood mononuclear cells were analysed by flow cytometry and cytokine release.


Fifty-six per cent of the original participants returned. Three of the original control group who did not return had lost all detectable C-peptide by the end of the 2 year trial. The C-peptide responses to a mixed-meal tolerance test were similar overall in the drug vs control group of participants but were significantly improved, with less loss of C-peptide, in drug-treated responders identified at 1 year. However, the improvements in C-peptide response were not associated with lower HbA1c levels or insulin use. Drug-treated responders showed a significantly increased frequency of programmed cell death protein 1-positive central memory and anergic CD8+ T cells at follow-up.


These findings suggest there is reduced decline in C-peptide and persistent immunological responses up to 7 years after diagnosis of diabetes in individuals who respond to teplizumab.

Trial registration NCT02067923; the protocol is available at (ITN027AI).


Anergy Anti-CD3 C-peptide Exhaustion T cells Teplizumab Type 1 diabetes 



Autoimmunity-Blocking Antibody for Tolerance




Fc receptor


Insulin autoantibodies


Killer cell lectin-like receptor G1


Microinsulin autoantibodies


Mixed-meal tolerance test


Monoclonal antibody


Peripheral blood mononuclear cell


Programmed cell death protein 1




Quantitative PCR


T cell immunoreceptor with Ig and ITIM domains


Regulatory T cells


Zinc transporter 8



The authors express their gratitude to L. Rink and L. Feldman (both from Yale Center for Clinical Investigation, Yale University, USA) for their help in recruitment and evaluation of participants.

Contribution statement

ALP, PPH, PC, SAL, PSL, SEG, CJG, PAG, AW, JD and KCH acquired and analysed data and wrote or revised the manuscript. KMH, JD, AW and WH analysed data and revised the manuscript. All of the authors approved the final version of the manuscript. KCH is the guarantor of this work.


This study was supported by grant 17-2013-501 from the Juvenile Diabetes Research Foundation and grant DK057846 from the National Institutes of Health. The flow cytometry analysis was sponsored by the Immune Tolerance Network and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565. ALP was supported by grant T32DK007058 from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Duality of interest

KCH is a member of the Scientific Advisory Board of Provention Biotech and a Scientific Advisor for Tiziana Life Sciences. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.

Supplementary material

125_2018_4786_MOESM1_ESM.pdf (212 kb)
ESM (PDF 211 kb)


  1. 1.
    Herold KC, Vignali DA, Cooke A, Bluestone JA (2013) Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 13(4):243–256. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Reed JC, Herold KC (2015) Thinking bedside at the bench: the NOD mouse model of T1DM. Nat Rev Endocrinol 11(5):308–314. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Naushad N, Perdigoto AL, Rui J, Herold KC (2017) Have we pushed the needle for treatment of type 1 diabetes? Curr Opin Immunol 49:44–50. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361(22):2143–2152. CrossRefPubMedGoogle Scholar
  5. 5.
    Pescovitz MD, Greenbaum CJ, Bundy B et al (2014) B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 37(2):453–459. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rigby MR, Harris KM, Pinckney A et al (2015) Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 125(8):3285–3296. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Orban T, Bundy B, Becker DJ et al (2014) Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37(4):1069–1075. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53(4):614–623. CrossRefPubMedGoogle Scholar
  9. 9.
    Herold KC, Gitelman SE, Ehlers MR et al (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766–3774. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Long SA, Thorpe J, DeBerg HA et al (2016) Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol 1(5):eaai7793. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tooley JE, Vudattu N, Choi J et al (2016) Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. Eur J Immunol 46(1):230–241. CrossRefPubMedGoogle Scholar
  12. 12.
    Long SA, Thorpe J, Herold KC et al (2017) Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. Cell Immunol 319:3–9. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hagopian W, Ferry RJ Jr, Sherry N et al (2013) Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 62(11):3901–3908. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790):487–497. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346(22):1692–1698. CrossRefPubMedGoogle Scholar
  16. 16.
    Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53(1):250–264. CrossRefPubMedGoogle Scholar
  17. 17.
    Herold KC, Gitelman SE, Willi SM et al (2013) Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 56(2):391–400. CrossRefPubMedGoogle Scholar
  18. 18.
    Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC (2014) Characterization of residual beta cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev 30(2):154–162. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Ana Luisa Perdigoto
    • 1
  • Paula Preston-Hurlburt
    • 2
  • Pamela Clark
    • 2
  • S. Alice Long
    • 3
  • Peter S. Linsley
    • 3
  • Kristina M. Harris
    • 4
  • Steven E. Gitelman
    • 5
  • Carla J. Greenbaum
    • 3
  • Peter A. Gottlieb
    • 6
  • William Hagopian
    • 7
  • Alyssa Woodwyk
    • 8
  • James Dziura
    • 9
  • Kevan C. Herold
    • 2
  • the Immune Tolerance Network
  1. 1.Division of Endocrinology, Department of Internal MedicineYale UniversityNew HavenUSA
  2. 2.Department of ImmunobiologyYale UniversityNew HavenUSA
  3. 3.Benaroya Research Institute at Virginia MasonSeattleUSA
  4. 4.Immune Tolerance Network, Biomarker & Discovery ResearchBethesdaUSA
  5. 5.Division of Pediatric Endocrinology and Diabetes CenterUniversity of California San FranciscoSan FranciscoUSA
  6. 6.Barbara Davis Center for Childhood DiabetesUniversity of Colorado School of MedicineAuroraUSA
  7. 7.Pacific Northwest Research InstituteSeattleUSA
  8. 8.Division of Epidemiology or BiostatisticsWestern Michigan UniversityKalamazooUSA
  9. 9.Department of Emergency MedicineYale UniversityNew HavenUSA

Personalised recommendations